SavedAdd your journal

Journals / Erciyes Tıp Dergisi / 2011 / Cilt: 33 - Sayı: 2

Akciğer adenokanserli hastada erlotinibe iyi klinik yanıt ve evre 3 cilt döküntüsü: Olgu sunumu

Good clinical response to erlotinib in a lung adenocancer patient and grade 3 skin rash: A case report

Ayhan LALE
Halit KARACA
Mustafa DİKİLİTAŞ
Veli BERK
Metin ÖZKAN
Özlem ER
Pages
145–148
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We report a case of lung adenocancer that we obtain good response together with severe skin rash by erlotinib therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Epidermal growth factor receptor (EGFR) has received a particular attention in lung cancer treatment.
📊
Key Findings & Data:Skin rash is the most common adverse event associated with erlotinib treatment and a significant correlation between severity of rash and survival has been found.
💡
Conclusion & Impact:We report a case of lung adenocancer that we obtain good response together with severe skin rash by erlotinib therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Epidermal growth factor receptor (EGFR) has received a particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase (EGFR-TKI), has been proven to prolong survival in non-small cell lung cancer (NSCLC) patients after first or second line chemotherapy. Skin rash is the most common adverse event associated with erlotinib treatment and a significant correlation between severity of rash and survival has been found. We report a case of lung adenocancer that we obtain good response together with severe skin rash by erlotinib therapy.

Özet

Akciğer kanseri tedavisinde epidermal büyüme faktörü reseptörü (EBFR) önemli bir ilgi görmektedir. Oral bir EBFR tirozin kinaz inhibitörü (EBFR-TKİ) olan erlotinibin, birinci veya ikinci sıra kemoterapi sonrasında küçük hücreli dışı akciğer kanseri (KHDAK) bulunan hastalarda sağkalımı uzattığı kanıtlanmıştır. Cilt döküntüsü erlotinib tedavisi ile ilişkili en sık yan etkidir ve döküntünün şiddeti ile sağkalım arasında önemli bir korelasyon olduğu bulunmuştur. Erlotinib tedavisi sonucu ciddi cilt döküntüsü ile beraber iyi cevap elde edilen bir akciğer adenokanseri olgusunu sunuyoruz.

🔖

Cite This Article

LALE, A., KARACA, H., DİKİLİTAŞ, M., BERK, V., ÖZKAN, M., ER, Ö. (2022). Akciğer adenokanserli hastada erlotinibe iyi klinik yanıt ve evre 3 cilt döküntüsü: Olgu sunumu. Erciyes Tıp Dergisi, Cilt: 33 - Sayı: 2, 145–148. https://ajindex.com/articles/502530

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Hoffmann–La Roche Ltd. Tarceva (erlotinib) product monograph. Rev ed. Mississauga, ON: Hoffmann–La Roche; April 1, 2008
  2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15): 1960–1966
  3. Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park) 2007; 21(11 Suppl 5):4–9
  4. Gerdes S, Mrowietz U. Follicular rash during therapy with erlotinib (Tarceva). J Dtsch Dermatol Ges 2006; 4(10): 855–857
  5. Gutzmer R, Werfel T, Kapp A, Elsner J. Cutaneous side effects of EGF-receptor inhibition and their management. (German) Hautarzt 2006; 57(6): 509–513
  6. Saif MW. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology. JOP 2006; 7(4): 337–348
  7. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8(Suppl 1): S7–S14
  8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 113–123
  9. Melosky B, Agulnik J, Assi H. Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 2008;15 (6):279–285
  10. Robert C, Soria JC, Spatz A, et al. Cutaneous side- effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6(7): 491–500
  11. Boeck S, Hausmann A, Reibke R, Schulz C, Heinemann V. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 2007; 18(9): 1109–1111
  12. Roskos L, Lohner M, Osborn K, et al. Low pharmacokinetic variability facilitates optimal dosing of ABX-EGF in cancer patients. Proc Am Soc Clin Oncol (abstract book). 2002
  13. Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006; 94(1): 85–92
  14. Perea S. Genotypic bases of EGFR inhibitors pharmacological actions. J Clin Oncol 2004; 22(14S): 3005
  15. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacological study of OSI–774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malign